Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

Summary

This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with needle/syringe or needle-free injector (PharmaJet Stratis™).

Timeline

Start

2013-01-22

Primary completion

2013-11-01

Completion

2013-11-21

Drugs

Indications